B&L Gains PureVision Insight From Ciba Vision's Ophthalmic Panel Review
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb's PureVision 30-day continuous wear contact lenses could undergo review by FDA's Ophthalmic Devices Panel as early as Sept. 20-21.
You may also be interested in...
Ciba Vision 30-Day Extended Wear Contact Lenses Get Panel Nod
Ciba Vision's Focus Night & Day contact lens indication statement should not include a claim of reduced dryness compared to hydrogel soft contacts, FDA's Ophthalmic Devices Panel recommended at a July 20 meeting in Rockville, Maryland.
Bausch & Lomb Envisions PureVision Lens For 30-Day Wear By 2001
Bausch & Lomb plans to seek FDA approval for an extended 30-day wear indication for its PureVision silicone-hydrogel soft contact lens by 2001.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.